Background illustration for clinical trials search

Paid Clinical Trials New Orleans

Discover 511 paid clinical trials in New Orleans, Louisiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 511

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for

Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma,

Location: New Orleans LA, Marrero LA, Metairie LA, Covington LA,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05256225

Phase3, Recruiting

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

for

Astrocytoma, IDH-Mutant, Grade 3

Location: New Orleans LA, Marrero LA, Metairie LA, Springfield MO,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 12+

Code: NCT07215910

Phase3, Recruiting

Continuous Glucose Monitoring (CGM) in an Underserved Population

for

Diabetes, Diabetes Mellitus, Diabetes Type 2

Location: New Orleans LA

Sponsor: Tulane University

Sex: All

Age: 18 - 70+

Code: NCT07135531

Recruiting

PPG to Predict Ejection Fraction and Other Echographic Data in the General Population

for

Valvular Heart Disease, Pericardial Disease, Cardiomyopathies

Location: New Orleans LA

Sponsor: Tulane University

Sex: All

Age: 18 - 70+

Code: NCT04843371

Recruiting

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

for

Gastric Adenocarcinoma,

Location: New Orleans LA, Atlanta GA, Dallas TX, Richardson TX,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 18+

Code: NCT07001748

Phase2, Phase3, Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for

Anatomic Stage I Breast Cancer AJCC v8,

Location: New Orleans LA, Pensacola FL, Baytown TX, Nassau Bay TX,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06876714

Phase3, Recruiting

Alleviant ALLAY-HFrEF Study

for

Heart Failure

Location: New Orleans LA, Houma LA, Pensacola FL, Decatur GA,

Sponsor: Alleviant Medical, Inc.

Sex: All

Age: 18+

Code: NCT06812533

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

for

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Location: New Orleans LA, Houston TX, Dallas TX, Plano TX,

Sponsor: Novo Nordisk A/S

Sex: All

Age: 18+

Code: NCT07207811

Phase3, Recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for

Locally Advanced Cervical Adenocarcinoma,

Location: New Orleans LA, Marrero LA, Metairie LA, Birmingham AL,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07061977

Phase3, Recruiting

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for

Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma,

Location: New Orleans LA, Marrero LA, Grenada MS, Columbus MS,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06958328

Phase3, Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: New Orleans LA, Jackson MS, Birmingham AL, Houston TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase2, Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

for

Advanced Cancer, Advanced Solid Tumors

Location: New Orleans LA, Nashville TN, Orlando FL, Denver CO

Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.

Sex: All

Age: 18 - 70+

Code: NCT06656390

Phase1, Phase2, Recruiting

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

for

Hematopoietic and Lymphatic System Neoplasm,

Location: New Orleans LA, Little Rock AR, Augusta GA, Anderson SC,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06279013

Recruiting

E-Mindfulness Approaches for Living After Breast Cancer

for

Breast Cancer, Depression

Location: New Orleans LA, Jackson MS, Grenada MS, Columbus MS,

Sponsor: NRG Oncology

Sex: All

Age: 18 - 50

Code: NCT06748222

Phase3, Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for

Prostate Cancer (Adenocarcinoma)

Location: New Orleans LA, Metairie LA, Baton Rouge LA, Jackson MS,

Sponsor: Canadian Cancer Trials Group

Sex: Male

Age: 18+

Code: NCT06592924

Phase3, Recruiting

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

for

Systemic Lupus Erythematosus,

Location: New Orleans LA, South Miami FL, Cleveland OH,

Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT06570798

Phase2, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for

Advanced Malignant Solid Neoplasm,

Location: New Orleans LA, Metairie LA, Gulfport MS, Mobile AL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase2, Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for

Triple Negative Breast Cancer

Location: New Orleans LA, Baton Rouge LA, Birmingham AL,

Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT05633654

Phase3, Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

for

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC),

Location: New Orleans LA, Nashville TN, Sarasota FL,

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06784193

Phase1, Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

for

Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7,

Location: New Orleans LA, Gainesville FL, Jacksonville FL,

Sponsor: Academic and Community Cancer Research United

Sex: Female

Age: 18+

Code: NCT04197687

Phase2, Recruiting

Paid Clinical Trials New Orleans

Filter results

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Continuous Glucose Monitoring (CGM) in an Underserved Population

PPG to Predict Ejection Fraction and Other Echographic Data in the General Population

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Interested in new trials?

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Alleviant ALLAY-HFrEF Study

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

E-Mindfulness Approaches for Living After Breast Cancer

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery